Bristol-Myers Squibb Company earnings overview

BMY FY2026 Q1 · Calendar Q2 2026

Bristol-Myers Squibb Company

Bristol-Myers Squibb posted a convincing Q1 2026 beat, with EPS of $1.58 (vs. $1.42 consensus, +11.3%) and revenue of $11.5B (vs. $10.9B consensus, +5.1%). Growth was anchored by double-digit expansion in early-life-cycle oncology assets Breyanzi and Opdualag, while the pipeline delivered tangible milestones: FDA breakthrough therapy designation for iberdomide (PDUFA August 17), positive Phase III interim data for an ADC in triple-negative breast cancer, and advancing late-stage readouts for Milvexian and oral CELMoDs. Management reaffirmed full-year guidance at the upper end of the range, backed by AI-driven R&D cycle-time reductions and disciplined capital allocation. The stock gained 5.2% on the report but has since drifted roughly 5.6% lower, and at $63.60 trades nearly in line with the $63.25 consensus target, suggesting the market is waiting for pipeline catalysts to materialize…